ERBB2 and breast carcinoma: Studies that have assessed HER2 discordance between primary breast cancer and tissue biopsy of metastatic disease report alterations in treatment administered due to rebiopsy, with some suggesting treatment response to anti-HER2 therapy with HER2 gain, however these data are very limited [18].